

Press Release

Revenue up by 25% and PAT up by 31%

(1st Quarter FY 2027 Consolidated Results)

Mumbai, 30th July, 2026: Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 1st quarter ended 30th June 2026.

Shareholders pay-out:

Today Board of Directors have approved interim dividend of Rs. 32 per share for face value of Rs. 2 per share amounting to Rs. 400 cr.

Q1 FY 2027 performance highlights (compared to Q1 FY 2026):

- Revenue from operations at **Rs. 1,626 cr.** against Rs. 1,303 cr.; **up 25%**.
- Adjusted EBITDA (excluding forex loss) at **Rs. 454 cr. & 28%** against Rs. 377 cr., up 21%.
- Profit after tax at **Rs. 334 cr.** against Rs. 255 cr.; PAT at 21%; **up 31%**.
- ROCE stood at a healthy level of 37% and RONW at 28%.

Segment wise performance:

(Rs. cr.)

Markets	Q1		Gwth%
	FY 2026	FY 2027	
Branded Generics			
India	₹ 409	₹ 509	24%
Asia	₹ 304	₹ 255	(16%)
Africa	₹ 228	₹ 295	30%
Sub-Total	₹ 941	₹ 1,059	13%
US Generic	₹ 310	₹ 487	57%
Africa Institution	₹ 38	₹ 70	83%
Total	₹ 1,289	₹ 1,616	25%

As per **IQVIA MAT June 2026**, our India branded generic performance exceeded IPM growth by **36%**. The higher growth came from new launches, which exceeded IPM by **76%** & volumes, which exceeded IPM by **40%**.

India branded generic Segment wise performance as per **IQVIA MAT June 2026** against IPM is as below:

Therapy	Growth %	
	IPM	Ajanta
Cardiology	15%	9%
Ophthalmology	10%	15%
Dermatology	8%	14%
Pain Management	10%	15%
Overall	11%	15%

ANDA status as at the end of Q1 FY 2027 is as below:

Particulars	Q1 FY 2027
Filed	-
Approval received	3
Launched	2
Total ANDA's commercialized	51
Awaiting approval with US FDA	17
Tentative approval	5

R&D expense:

(Rs. cr.)

Particulars	FY 2026	FY 2027	% to Revenue
Q1	₹ 56	₹ 66	4%

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 33+ countries. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa.

Company's state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India.

For the last 3 financial years, company has posted healthy Revenue and PAT CAGR of 14%.

Earnings Conference Call

The Company will host an Earnings Conference Call at 16:15 hrs. IST (18:45 hrs. SST/HKT, 11:45 hrs. BST, 06:45 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

Date and Time	July 30, 2026 at 16:15 – 17:15 hrs IST 18:45 – 19:45 hrs SST/HKT 11:45 – 12:45 hrs BST 06:45 – 07:45 hrs US ET
Dial-in Numbers	
Diamond pass link for faster access	Click here to register
Universal Access	Primary Access: (+91 22 6280 1542) (+91 22 7115 8372)
International Toll Free	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

For convenience and faster connectivity to the conference, kindly follow below steps:

1. Register through the Diamond pass link.
2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.
3. Dial the 'conference Dial-in number' you will receive on your email.
4. On system prompt dial the PASSCODE followed by # key.
5. On system prompt enter the PIN followed by # key.
6. If the line gets disconnected, you need to dial the 'conference dial-in number' again and follow the necessary steps.

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com

For regular updates follow us on x.com – <https://x.com/AjantaPharmaLtd>

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Corporate Identity Number (CIN): L24230M9M979PLC022059

Safe Harbour Statement

Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2026

Particulars	3 months ended			₹ in Crore
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
	Unaudited	Audited (Refer Note 3)	Unaudited	Audited
Income				
Revenue from operations	1,625.96	1,421.64	1,302.65	5,452.86
Other income (Refer note 5)	70.90	61.43	26.33	172.07
Total Income	1,696.86	1,483.07	1,328.98	5,624.93
Expenses				
Cost of materials consumed	296.51	256.76	207.08	916.51
Purchases of stock-in-trade	66.92	71.35	51.63	229.79
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(35.58)	(23.30)	17.17	37.46
Employee benefits expense	381.11	340.72	302.90	1,291.15
Finance costs	3.18	2.36	5.26	16.11
Depreciation and amortisation expense	44.50	45.37	41.29	173.14
Other expenses (Refer note 5)	493.42	442.70	372.52	1,583.12
Total Expenses	1,250.06	1,135.96	997.85	4,247.28
Profit before and after exceptional items but before tax	446.80	347.11	331.13	1,377.65
Tax Expense				
Current Tax (net)	102.72	61.40	73.50	300.08
Deferred Tax (net)	9.86	19.01	2.29	21.57
Profit after tax	334.22	266.70	255.34	1,056.00
Other Comprehensive Income (OCI)				
Items that will be reclassified subsequently to profit or loss	(0.94)	15.83	3.41	29.39
Income tax relating to Items that will be reclassified subsequently to profit or loss	-	-	-	-
Items that will not be reclassified subsequently to profit or loss	(5.11)	3.51	(4.99)	(0.48)
Income tax relating to Items that will not be reclassified to profit or loss	1.79	(1.23)	1.74	0.17
Other Comprehensive Income / (loss), net of tax	(4.26)	18.11	0.16	29.08
Total Comprehensive Income for the period / year	329.96	284.81	255.50	1,085.08
Paid-up Equity Share Capital (Face value of ₹ 2 each)	25.07	25.07	25.07	25.07
Other Equity				4,502.02
Earnings Per Share (Face value of ₹ 2 each)				
(a) Basic - in ₹	26.75	21.35	20.44	84.53
(b) Diluted - in ₹	26.72	21.34	20.43	84.51

Notes :

1. The above consolidated financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 July 2026. The statutory auditors have expressed an unmodified conclusion. The review report has been filed with the stock exchange and is available on company website. The consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. The consolidated unaudited financial results of the Company, its wholly owned subsidiaries ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.

3. The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2025.

4. Board of Directors have approved 1st interim dividend of ₹ 399.79 Crore for financial year 2026-27 to its shareholders @ ₹ 32 per share on the face value of ₹ 2 per share.

5. Other income / Other expense includes :

₹ in Crore	3 months ended		Year Ended	
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
Foreign exchange gain (in other income)	50.47	44.37	9.38	97.17
Foreign exchange loss (in other expense)	30.59	41.70	25.15	103.04

6. In August 2025, the Income Tax Authorities carried out search operations and the Company filed the return for the block period from 1 April 2019 to 17 November 2025 on 6 April 2026. Pending any subsequent communication from the concerned authorities in this regard, the consequent impact on the consolidated financial results for the quarter ended 30 June 2026, if any, is currently not ascertainable.

7. The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".

8. The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

By order of the Board
For Ajanta Pharma Ltd.


Yogesh M. Agrawal
Managing Director

Mumbai, 30 July 2026



Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2026

Particulars	3 months ended			Year Ended
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
	Unaudited	Audited (Refer Note 2)	Unaudited	Audited
Income				
Revenue from operations	1,488.67	1,210.53	1,208.56	4,845.92
Other income (Refer note 4)	70.82	62.98	40.63	204.40
Total Income	1,559.49	1,273.51	1,249.19	5,050.32
Expenses				
Cost of materials consumed	296.51	256.77	207.08	916.52
Purchases of stock-in-trade	67.20	57.99	50.29	218.06
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(47.06)	(49.56)	6.08	(57.32)
Employee benefits expense	352.81	313.49	280.96	1,194.05
Finance costs	0.76	(0.74)	0.73	2.59
Depreciation and amortisation expense	43.31	44.16	40.31	168.77
Other expenses (Refer note 4)	422.51	393.79	334.75	1,376.62
Total Expenses	1,136.04	1,015.90	920.20	3,819.29
Profit before and after exceptional items but before tax	423.45	257.61	328.99	1,231.03
Tax Expense				
Current Tax (net)	101.63	67.33	70.73	276.61
Deferred Tax (net)	6.35	(7.00)	3.29	7.60
Profit after tax	315.47	197.28	254.97	946.82
Other Comprehensive Income (OCI)				
Items that will not to be reclassified subsequently to profit or loss	(5.11)	3.51	(4.99)	(0.48)
Income tax relating to items that will not be reclassified to profit or loss	1.79	(1.23)	1.74	0.17
Other Comprehensive Income / (loss), net of tax	(3.32)	2.28	(3.25)	(0.31)
Total Comprehensive Income for the period / year	312.15	199.56	251.72	946.51
Paid-up Equity Share Capital (Face value of ₹ 2 each)	25.07	25.07	25.07	25.07
Other Equity				4,198.46
Earnings Per Share (Face value of ₹ 2 each)				
(a) Basic - in ₹	25.25	15.79	20.41	75.79
(b) Diluted - in ₹	25.22	15.79	20.40	75.77

Notes :

1. The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 July 2026. The statutory auditors have expressed an unmodified conclusion. The review report has been filed with the stock exchange and is available on company website. The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2025.

3. Board of Directors have approved 1st interim dividend of ₹ 399.79 Crore for financial year 2026-27 to its shareholders @ ₹ 32 per share on the face value of ₹ 2 per share.

4. Other income / Other expense includes :

₹ in Crore	3 months ended			Year Ended
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
Dividend from subsidiaries (in other income)	-	-	21.47	36.68
Foreign exchange gain (in other income)	50.47	46.16	7.32	99.66
Foreign exchange loss (in other expense)	16.19	41.70	25.15	103.04

5. In August 2025, the Income Tax Authorities carried out search operations and the Company filed the return for the block period from 1 April 2019 to 17 November 2025 on 6 April 2026. Pending any subsequent communication from the concerned authorities in this regard, the consequent impact on the standalone financial results for the quarter ended 30 June 2026, if any, is currently not ascertainable.

6. The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".

7. The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

By order of the Board
For Ajanta Pharma Ltd.



Yogesh M. Agrawal
Managing Director

Mumbai, 30 July 2026



Corporate Identity Number - L24230MH1979PLC022059

Registered Office: Ajanta Tower, 54-A, M Vasanti Road, Chakala, Andheri (E), Mumbai- 400 093. Tel.: +91-22-6060 9000